Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer
- 30 April 2008
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 3 (4), 351-357
- https://doi.org/10.1097/jto.0b013e318168c7e9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Perforated Viscus in a Patient with Non-small Cell Lung Cancer Receiving BevacizumabJournal of Thoracic Oncology, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Nasal Septum Perforation in a Bevacizumab-Treated Patient with Metastatic Breast CancerThe Oncologist, 2006
- Angiogenesis and Lung Cancer: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2005
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971